BBC News

Inside the secretive and lucrative world of orchid breeding

Inside the secretive and lucrative world of orchid breeding

The Hidden Prosperity of Orchid Breeding

Creating a new orchid variety is a marathon, not a sprint, often demanding ten years of rigorous effort before the flower reaches the consumer. Despite the immense financial potential of the global orchid industry, which generates hundreds of millions of dollars annually, the rivalry among breeders to cultivate the next stunning bloom is fierce. Consequently, modern orchid development relies as heavily on advanced laboratories as it does on traditional greenhouses.

According to Floricultura, a prominent Dutch breeding firm, centuries of human-driven selective breeding and propagation have resulted in a "disaster" of genetic backgrounds for many commercial orchids. This genetic complexity makes it incredibly challenging to forecast the traits of new plant breeds. To overcome this uncertainty, Floricultura and other industry players are utilizing genetic markers to accelerate selective breeding. These markers target specific characteristics such as color, shape, disease resistance, and flowering duration.

This technological approach allows breeders to evaluate young plants immediately, rather than waiting three years for them to bloom. If a plant does not meet the desired criteria, it can be discarded at the outset. "If a few thousand cross breeds [come] from the lab, we can screen them based on the marker and just select the ones that have the marker that you search for," explained Wart van Zonneveld, Floricultura’s research and development manager. He noted that these markers serve as indicators for desired or undesired traits, depending on which is more practical to identify.

These so-called "novel breeding techniques" are tightly guarded trade secrets. Each company develops its own unique genetic markers and processes to create distinctive varieties, as this proprietary knowledge is the key to their competitive edge. "We keep it to ourselves because it's lots of investment," van Zonneveld stated. However, Paul Arens, an ornamental plant breeding researcher at Wageningen University, clarified that despite the high-tech appearance, the core process remains traditional. "It's still breeding, you have to make a cross, and we cannot just pick out a piece of DNA and put it back that easily," he said. Arens, who contributed to a government-backed initiative that facilitates information sharing among participating companies, added, "The foundation is still what we are doing for 100 years already. You take two plants, you look at their characteristics, and you make a cross. But [the breeders] have white lab coats, [and] they're doing all kinds of research with markers, with genomics, on plant health."

Genetics also play a crucial role in safeguarding intellectual property. In Europe, new varieties are protected through breeders' rights, while the United States utilizes patents. "If a company makes a new orchid, then [it] would like the sole right to commercialize this orchid," Arens explained. "Otherwise, somebody else can just buy it in the shop, multiply it and sell it himself." To secure these rights, a researcher must verify that the new variety is distinct, stable, and uniform compared to existing market offerings.

While breeders' rights and patents are granted based on physical descriptions rather than direct DNA analysis, genetic testing is vital for selecting the appropriate reference plants for comparison. "It's just like what we do in forensic science. You run markers that are at different positions in the DNA and that gives you a pattern and then you have a chance to match it or not," Arens said.

Floricultura operates exclusively in the B2B sector, selling neither to the general public nor to garden centers. Instead, their business model focuses on developing new varieties for large-scale cultivators. The company currently holds over 180 varieties in its catalog, with several hundred more in the pipeline, driven by the relentless demand for novelty. "You can't stop, because it takes so long to develop new varieties," said Stefan Kuiper, the company’s breeding manager. "You have to go on, [or] you will be behind."


Source: BBC News Generated at: 2026-05-14 23:03:16 UTC

Related Articles

Bloomberg

Trump to Keep Audit Immunity, Pulte Named New Acting DNI, More

Trump retains audit immunity, and Pulte is appointed Acting DNI.

Bloomberg

Stock Movers: HPE, Victoria's Secret, Shake Shack (Podcast)

Bloomberg’s podcast highlights market movers HPE, Victoria’s Secret, and Shake Shack, analyzing their recent stock perfo...

Bloomberg

Balance of Power: Trump Aims to Calm Lebanon Tensions (Podcast)

Bloomberg podcast discusses Trump’s efforts to de-escalate tensions in Lebanon, aiming to restore regional stability thr...

Bloomberg

Trump Audit Immunity Intact, Pulte Named Acting DNI, More

Trump’s audit immunity remains intact, and Pulte has been named acting Director of National Intelligence.

Google Needs More Money
Bloomberg

Google Needs More Money

Google unveiled new AI tools and a revamped search interface at its 2026 I/O conference, reinforcing its multi-billion-d...

Reuters

IEA forecasts chance of critically low stockpiles before peak summer demand

The IEA warns of critically low stockpiles before peak summer demand. This forecast highlights potential energy shortage...